San Diego-based Tracon Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration (AMD) and fibrotic diseases, announced that Ronald Shazer has been appointed as chief medical officer.
Shazer was most recently senior director, clinical lead oncology at Pfizer where he led the clinical development of multiple immuno-oncology compounds including antibody drug conjugates, dual targeting T-cell engaging antibodies, and small molecules. Prior to Pfizer, Shazer was director of clinical research oncology at Bristol-Myers Squibb from 2011 to 2013 and served as the study lead on the registrational study for elotuzumab, which received FDA breakthrough therapy designation in 2014. Prior to Bristol-Myers Squibb, Shazer was head of clinical development at Arena Pharmaceuticals during the filing of the NDA for lorcaserin (Belviq).
Shazer held academic positions in the Department of Medicine at the UC San Diego, UCLA School of Medicine and Cedars-Sinai Medical Center.
He earned his BA in economics from the UC San Diego, MD from the New York Medical College, and MBA from the Anderson School of Management, UCLA. He completed his residency in internal medicine at Cedars-Sinai Medical Center in 2004.